Polatuzumab Vedotin

clinical grade

BATCH NUMBER: B1008H10

552,00 

Therapeutic Polatuzumab Vedotin antibody from the original Polivy® commercial drug

In stock

Product specifications:​

  • Quality Standard clinical-grade
  • Product Concentration 20 mg/mL
  • Volume per vial 50 µL
  • Quantity per vial 1 mg
  • Origin of the commercial drug DE
  • Batch Number B1008H10
  • Storage Temperature -80 °C
  • Original therapeutic expiry date: 2024.06

Our products are for research use only. The “therapeutic expiration date” implies expiry date for patient administration and is not applicable to the shelf life of the aliquot. Aliquot storage at -86°C ensures fully functional molecules even after the mentioned expiry date.

Product Information:

Evidentic offers repackaged finished pharmaceutical products (e.g RMP/RLD). We refer to the repackaged RMP/RLD products synonymously as drug aliquots or aRMP, or short: aliquots.

We offer batches of original drug aliquots in low-binding Eppendorf tubes for research use only. We provide license-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

As ‘raw material’ for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP.
Drug aliquots are manufactured by repackaging RMP in a qualified laboratory. The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer. Repackaging of RMP includes the following steps: opening the secondary and primary RMP containers and transferring the specified volumes of RMP into an Eppendorf 0.5 ml low-binding (or similar) tube. If the RMP is a lyophilized powder and not a highly concentrated solution, reconstitute the RMP according to the original manufacturer’s instructions and then aliquot as a highly concentrated solution.
For identification purposes, drug aliquots are labeled with the date of aliquoting, the original lot number of the RMP, the original expiration date of the RMP, the name of the active ingredient (INN), and a unique identification code.
Immediately after aliquoting, drug aliquots are stored at either 2-8 °C or -86 °C for long-term storage. All drug aliquots stored at 2-8 °C are transferred to -86 °C at least two weeks before the expiration date of the original RLD/RMP is reached. Further quality or functional testing are not performed on the drug aliquots.  

Class of molecule

Isotype

Host cells

Chinese hamster ovary (CHO) cells

Prepared from (Reference drug)​

Polivy®

Therapeutic Area

Therapeutic Indications

Mechanism of Action (MoA)

Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potentanti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing ofmalignant B-cells. The polatuzumab vedotin molecule consists of MMAE covalently attached to ahumanized immunoglobulin G1 monoclonal antibody via a cleavable linker. The monoclonal antibodybinds with high affinity and selectivity to CD79b, a cell surface component of the B-cell receptor.CD79b expression is restricted to normal cells within the B-cell lineage (with the exception of plasmacells) and malignant B-cells; it is expressed in > 95% of diffuse large B-cell lymphoma. Upon bindingCD79b, polatuzumab vedotin is rapidly internalized and the linker is cleaved by lysosomal proteasesto enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells byinhibiting cell division and inducing apoptosis.

Pharmacotherapeutic group​​

Antineoplastic agent

List of Excipients​

Succinic acid
Sodium hydroxide (for pH-adjustment)
Sucrose
Polysorbate 20 (E 432)

Batch specific analytical data available

Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API).

Polatuzumab Vedotin

BATCH NUMBER: B1008H10

Request an individual offer​

+ download a free sample​

1. Choose your(s) method(s) of interest
2. Provide your contact details
3. Send us your request and download a free sample report


Please provide your contact information


send us your inquiry and download a free sample file


More , Reference Drugs as Aliquots

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price from
Nectin-4
Antibody-drug conjugate (ADC)
Padcev®
10 mg/mL
1 mg
-80 °C
2026.08
345,00 
view product
Max: 5
Min: 1
Step: 1
Nectin-4
Antibody-drug conjugate (ADC)
Padcev®
10 mg/mL
1 mg
-80 °C
2026.12
345,00 
view product
Max: 10
Min: 1
Step: 1
CD33
Antibody-drug conjugate (ADC)
Mylotarg®
1 mg/mL
0,1 mg
-80°C
2024.08
1.161,00 
view product
Max: 10
Min: 1
Step: 1
CD33
Antibody-drug conjugate (ADC)
Mylotarg®
1 mg/mL
0,1 mg
-80°C
2025.03
1.161,00 
view product
Max: 10
Min: 1
Step: 1
CD22
Antibody-drug conjugate (ADC)
Besponsa®
0,25 mg/mL
0,02 mg
tba
tba
1.502,00 
view product
Max:
Min: 8
Step: 1
CD19
Antibody-drug conjugate (ADC)
Zynlonta®
5 mg/mL
0,5 mg
tba
tba
2.474,00 
view product
Max: 10
Min: 9
Step: 1
FRɑ
Antibody-drug conjugate (ADC)
Elahere®
5 mg/mL
2 mg
tba
tba
1.817,00 
view product
Max: 10
Min: 8
Step: 1
Trop-2-directed ADC
Antibody-drug conjugate (ADC)
Trodelvy®
10 mg/mL
4 mg
-80°C
2025.08
308,00 
view product
Max: 10
Min: 1
Step: 1
Tissue factor (TF)
Antibody-drug conjugate (ADC)
Tivdak®
10 mg/mL
1 mg
tba
tba
1.665,00 
view product
Max: 10
Min: 7
Step: 1
HER2
Antibody-drug conjugate (ADC)
Enhertu®
20 mg/mL
2 mg
-80 °C
2027.05
497,00 
view product
Max: 7
Min: 1
Step: 1
HER2
Antibody-drug conjugate (ADC)
Kadcyla®
20 mg/mL
2 mg
-80 °C
2027.10
386,00 
view product
Max: 10
Min: 1
Step: 1

Not looking for Polatuzumab Vedotin B1008H10?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Thank you for your interest in our services.

We will respond to you within one working day. You can now download your sample report.